We bring
hope to life

People in dire medical need deserve
life-saving treatment.

Sept 11, 2021

Sept 11, 2021

Ongoing Communications with the US Food and Drug Administration

NRx has responded to the information request issued by the FDA with regard to …

Sep. 8, 2021

NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Right to Try

Right to Try

For US-licensed physicians

who wish to obtain Aviptadil under Right to Try law for Critical COVID-19 patients with no therapeutic alternative

Pipeline

Pipeline

Research Pipeline

Our product candidates include compounds in Phase 2, and Phase 3 trials for COVID-19-related Lung Injury and Acute Respiratory Failure (ARDS) in partnership with Relief Therape…

ZYESAMI™ (Aviptadil)

ZYESAMI™ (Aviptadil)

ZYESAMI™

ZYESAMI™ (Aviptadil, previously RLF-100™), a synthetic form of human Vasoactive Intestinal Peptide (VIP) has been granted FDA Fast Track Designation for the investigational treatment of

NRX-100/NRX-101

NRX-100/NRX-101

NRX-100/NRX-101

NRx’s investigational drug regimen NRX-100/NRX-101, if approved by the FDA, would be the first sequential medicine regimen to include an oral therapeutic to treat Bipolar Depression..

Bipolar Depression

Bipolar Depression

Bipolar Depression in Patients with Acute Suicidal Ideation and Behavior (ASIB)In the United States, More than 100 People End Their Lives Each Day

Zyesami and NRX-100/NRX-101 are investigational therapies and have not been approved for human use by the Food and Drug Administration or European Medicines Agency.

Committed to
Life-Saving Treatments

NRx creates innovative, life-saving treatments to address unmet medical needs and bring hope to those with chronic conditions.

Learn More
NRx NRx